Open in interactive viewer → charts, metric popovers & call review

Roivant's $31 Million Proof Point — and the Trial That Read Out Before the FDA Did

Five weeks of LISRAYA revenue, an unexpected RA p-value, a quiet Sjögren's retreat, and a launch whose inventory math nobody will pin down
ROIV · Earnings Call · 2026-11-09

The first real revenue line, wrapped in fog

Roivant spent a decade as a company valued almost entirely on optionality. This quarter it became, for the first time, a company with a product on the market — and the market got exactly five weeks of data to argue about. LISRAYA (brepocitinib) was approved in late August for dermatomyositis and booked $31 million of net revenue in that stub period, against a total revenue base that in the last filed quarter was $1 million. That comparison is the whole investment case in one line. Management was unusually disciplined about not helping. Matt Gline confirmed “there were hundreds of patients on paid drug at the end of the quarter” — Matthew Gline, Chief Executive Officer · 2026-11-09 and "many hundreds" by early November, with hundreds of prescribers already writing. But pressed repeatedly on how $31 million squares with that patient count, he declined. The explanation offered is a stocking effect: revenue is booked when specialty pharmacies buy, and pharmacies bought ahead of demand. “there was a meaningful amount of undispensed drug that specialty pharmacies were holding as of 9/30. All of what they were holding at that point has now been dispensed” — Matthew Gline, Chief Executive Officer · 2026-11-09 — implying a tailwind to the September quarter and a modest headwind to December. That is a clean, plausible answer. It is also unfalsifiable until the next print. The genuinely new vocabulary here is paid drug and specialty pharmacy — logistics language that never appeared in Roivant's prior calls, because there was nothing to ship. Equally new: payer dynamics, which Gline described as "clean so far" with access ranging from a single prior-immunosuppressant requirement at large national plans to considerably tighter controls elsewhere. Any investor in this name is now underwriting reimbursement execution, not just clinical risk. That is a different company.

A p-value nobody planned for

The louder event was unplanned. Roivant released Period 2 of the IMVT-1402 randomized-withdrawal study in difficult-to-treat RA because, simply, it worked. Roughly 92.5% of patients on 600 mg maintained an ACR20 response at week 28 versus about 75% on placebo; ACR50 separated at 80% versus 56%. The company's own thesis — deep IgG suppression — got its cleanest validation yet, because the 300 mg arm looked like placebo. That is a commercially valuable negative: it tells you the drug is not a commodity FcRn.

Those discussions are ongoing. Frankly, we had to disclose this data at this point because we hit a p-value unexpectedly.

Matthew Gline, Chief Executive Officer · 2026-11-09
That single sentence is the story of the quarter. On the August call, the stated plan was to deliver the data and the FDA path together.

my dream, our dream for the second half of this year is that we can come back with everything tied as nicely into a bow as possible, which is to say the period 2 data, the FDA conversation...

Matthew Gline, CEO · 2026-08-06
The bow came untied. In August, Gline had also cautioned that “the results of that study may inform whether it is usable or not as one of our pivotal studies” — Matthew Gline, CEO · 2026-08-06 — the base case was that a randomized-withdrawal design might serve as one of two registrational trials. Now, with statistically significant data in hand, management believes a straight randomized controlled trial is the likelier Phase 3 shape: “I think it's relatively unlikely this will be a randomized withdrawal study” — Matthew Gline, Chief Executive Officer · 2026-11-09. The randomized withdrawal construct has flipped from an asset to a stepping stone.

What management stopped saying

The most telling line on the call was a subtraction. Sjögren's — pitched as recently as last November as a place where Roivant had "a real shot at best-in-class" — is being quietly wound down. “we said today we're probably not expecting to address Sjogren's” — Matthew Gline, Chief Executive Officer · 2026-11-09, Gline said, citing a futility analysis that "failed in 500 patients," alongside competitor experience at J&J and Novartis. The prior enthusiasm was not wrong at the time; it was simply overtaken. Combined with the earlier CLE miss, the 1402 franchise is narrowing toward the indications where depth of IgG suppression is unambiguous: Graves', myasthenia gravis, and now this refractory RA population of roughly 85,000 US patients. The forward calendar is dense — Graves' and MG data in 2027, an NIU supplemental filing, mosliciguat Phase 3 enrolling in PH-ILD with the 56% placebo-adjusted PVR reduction and 35-meter six-minute walk already banked, plus an Investor Day on December 9. But notice the cash allocation: management repurchased roughly $280 million of stock in six months, about 9.4 million shares. When a company with three late-stage franchises is buying its own equity, it is telling you something about how it weighs the pipeline against the share price.

Cash, and the price of the option

None of this is a funding story. The last filed balance sheet carried $5.4 billion of effective net cash at July 31; management put cash at $4.2 billion on September 30, including litigation receipts from Moderna. R&D ran $202 million, up 32% year over year and the highest in Roivant's history, with Phase 3 spend in NIU, PH-ILD and RA still ahead. Which brings back the valuation. 3,395x trailing revenue is not a multiple; it is a placeholder for expectations. The tape reflects ambivalence rather than conviction: shares are up about 15% over the last 90 trading days into this print, a single quiet up-segment, having traveled a violently segmented multi-year path to triple-digit cumulative gains. Nobody has yet been forced to mark the franchise to a launch curve. The quarter therefore sets up a genuine fork. If LISRAYA's payer access holds and the December quarter's inventory headwind is truly "modest," Roivant has the commercial proof that its whole model — Vants, capital allocation, mechanism selection — was worth the wait. If the $31 million was mostly pharmacy shelf-stocking into a controlled-access wall, the RA p-value and the mosliciguat data will do the heavy lifting for another year. Gline's closing note — "there is no substitute in this business for generating clinical data that matters" — is true, and also conveniently avoids the question now in front of him: whether the data can be sold.